Pilot study assessing 18F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation☆

DSpace/Manakin Repository

Pilot study assessing 18F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation☆

Citable link to this page

 

 
Title: Pilot study assessing 18F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation☆
Author: Cho, Linda P.; Kim, Chun K.; Viswanathan, Akila N.

Note: Order does not necessarily reflect citation order of authors.

Citation: Cho, Linda P., Chun K. Kim, and Akila N. Viswanathan. 2015. “Pilot study assessing 18F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation☆.” Gynecologic Oncology Reports 14 (1): 34-37. doi:10.1016/j.gore.2015.10.003. http://dx.doi.org/10.1016/j.gore.2015.10.003.
Full Text & Related Files:
Abstract: Objective: The role of F-18-fluorothymidine (FLT) PET-CT imaging in the evaluation of gynecologic cancers has not been established. We sought to evaluate (FLT) PET-CT imaging in gynecologic cancers by comparing standard uptake values (SUVs) of FLT with F-18-fluorodeoxyglucose (FDG) PET in the primary tumor at diagnosis, and assess FLT uptake immediately following concurrent chemoradiotherapy (chemoRT). Methods: In this pilot study, patients treated for cervical (5) or vaginal (1) cancer underwent FLT-PET and FDG-PET scanning at diagnosis (FLT1 and FDG1). Five patients (4 cervical and 1 vaginal) also underwent FLT-PET within 1–3 weeks after chemoRT before brachytherapy (FLT2). Wilcoxon rank-sum test was used to compare the FLT1 and FDG1 parameters. Results: Median age at diagnosis was 61-years (range, 33–72). Cervical cancers were staged as IB2 (n = 1, 20%), IIB (n = 1, 20%), IIIB (n = 1, 20%) and IVA (n = 2, 40%) and the single vaginal cancer was staged IIIB. The most common histology was squamous cell carcinoma (n = 3, 50%) followed by adenocarcinoma (n = 2, 33%) and clear-cell adenosquamous carcinoma (n = 1, 17%). Median tumor SUVmax at diagnosis was 7.8 on FLT1-PET (3.9–14.2) versus 11.6 (5.9–23.2) on FDG1-PET (p = 0.15). Tumor SUVmax of FLT declined 54%–100% after chemoRT. Conclusion: The tumor SUV of FLT at diagnosis was lower than that of FDG-PET. FLT uptake was markedly decreased after chemoRT. Results indicate that there may not be a significant effect of inflammation on FLT uptake in gynecologic cancers. FLT may be a useful tool when assessing the effects of chemoRT on gynecologic malignancies and planning for postchemoRT brachytherapy treatments.
Published Version: doi:10.1016/j.gore.2015.10.003
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688880/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:24984052
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters